We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Compound Prevents Breast Cancer in Mice

By Biotechdaily staff writers
Posted on 08 Nov 2004
A new compound developed through the combined use of chemistry, biology, bioinformatics, pharmacology, and mathematics has been shown capable of preventing breast cancer in mice.

The compound was developed by researchers at Parker Hughes (Roseville, MN, USA). Called Compound 003, the compound prolonged cancer-free survival in transgenic mice that otherwise invariably develop HER2-positive metastatic breast cancer. The compound is a novel cytotoxic nucleoside analog and was well tolerated in both mice and rats without toxicity.

The research results were published in the November 2004 issue of the international medical journal Arzneimittelforschung. Women with HER2-positive breast cancer have a greater risk for recurrence of their breast cancer and an increased risk of mortality. Roughly 40,000 women in the United States alone die each year from breast cancer.




Related Links:
Parker Hughes

Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Verification Panels for Assay Development & QC
Seroconversion Panels
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Rheumatoid Factors (RF) Test
Rheumatoid Factors (RF)

Latest BioResearch News

Genome Analysis Predicts Likelihood of Neurodisability in Oxygen-Deprived Newborns
08 Nov 2004  |   BioResearch

Gene Panel Predicts Disease Progession for Patients with B-cell Lymphoma
08 Nov 2004  |   BioResearch

New Method Simplifies Preparation of Tumor Genomic DNA Libraries
08 Nov 2004  |   BioResearch